Translational Cancer Research Unit, GZA Hospitals, Sint-Augustinus, Antwerp, Belgium; Iridium Kankernetwerk, Antwerp, Belgium; Center for Oncological Research (CORE), Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Antwerp, Belgium.
Translational Cancer Research Unit, GZA Hospitals, Sint-Augustinus, Antwerp, Belgium; Center for Oncological Research (CORE), Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Antwerp, Belgium; Histogenex, Antwerp, NV, Belgium.
Semin Cancer Biol. 2021 Jun;71:33-41. doi: 10.1016/j.semcancer.2020.07.002. Epub 2020 Jul 28.
The histopathological growth patterns (HGPs) of liver metastases of colorectal cancer and of several other tumor types predict outcome of patients in multiple studies. The HGPs of liver metastases have a prognostic but also a predictive value with one of the growth patterns, the replacement growth pattern, related to resistance to systemic treatment. Given that the HGP can only be assessed in a reliable manner when a surgical resection of the metastasis has been performed, this biomarker cannot be exploited to the full. For example, HGPs can at this moment, not be used to decide whether patients with liver metastatic breast or colorectal cancer will benefit or not from locoregional treatment, such as surgery or radiotherapy, and from peri-operative systemic treatment. In this review we highlight studies that suggest that the HGPs of liver metastases can be identified by medical imaging. Although still to be confirmed by a prospective multicenter approach, some studies indeed achieve a high accuracy in predicting the HGPs by applying radiomic algorithms on CT- or MR-images of liver metastases. This is an important step towards a treatment planning of patients with liver metastatic cancer that takes into account the biology and the progression kinetics of the metastases.
在多项研究中,结直肠癌和其他几种肿瘤类型的肝转移的组织病理学生长模式(HGPs)可预测患者的预后。肝转移的 HGPs 具有预后价值,也具有预测价值,其中一种生长模式——替代性生长模式与对全身治疗的耐药性有关。鉴于只有在对转移灶进行手术切除后才能可靠地评估 HGP,因此该生物标志物不能充分发挥作用。例如,目前不能通过 HGPs 来确定患有肝转移性乳腺癌或结直肠癌的患者是否会从局部区域治疗(如手术或放疗)和围手术期全身治疗中获益。在这篇综述中,我们强调了一些研究,这些研究表明可以通过医学成像来识别肝转移的 HGPs。尽管还需要通过前瞻性多中心方法来证实,但一些研究确实通过在 CT 或 MR 图像上应用放射组学算法来预测 HGPs,实现了较高的准确性。这是朝着考虑转移生物学和进展动力学的肝转移性癌症患者治疗计划迈出的重要一步。